Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C10H12ClN3O3S |
| Molecular Weight | 289.739 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1NC(=O)C2=CC(=C(Cl)C=C2N1)S(N)(=O)=O
InChI
InChIKey=AGMMTXLNIQSRCG-UHFFFAOYSA-N
InChI=1S/C10H12ClN3O3S/c1-2-9-13-7-4-6(11)8(18(12,16)17)3-5(7)10(15)14-9/h3-4,9,13H,2H2,1H3,(H,14,15)(H2,12,16,17)
| Molecular Formula | C10H12ClN3O3S |
| Molecular Weight | 289.739 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/18600270Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19636250
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18600270
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19636250
Quinethazone (brand name Hydromox) is a thiazide diuretic used to treat hypertension. The antihypertensive mechanism of quinethazone is less well understood. This drug was discovered in a period when only isoform carbonic anhydrases (CAs) II was known and considered physiologically/pharmacologically relevant. Recently was studied that quinethazone considerably inhibit other isozymes known nowadays to be involved in critical physiologic processes. Thiazides like quinethazone also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. Common side effects include dizziness, dry mouth, nausea, and low potassium levels. Thiazides may increase the toxicity of allopurinol, anesthetics, antineoplastic, calcium salts, diazoxide, digitalis, lithium; loop diuretics, methyldopa, nondepolarizing muscle relaxants, vitamin D; amphotericin B and anticholinergics may increase the toxicity of thiazides.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2095180 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18600270 |
|||
Target ID: CHEMBL1876 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20528637 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | HYDROMOX Approved UseUnknown Launch Date1963 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/mmx/quinethazone.html
50-100 mg once daily; usual maximum: 200 mg/day
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:21:32 GMT 2025
by
admin
on
Mon Mar 31 18:21:32 GMT 2025
|
| Record UNII |
455E0S048W
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
C03BA02
Created by
admin on Mon Mar 31 18:21:32 GMT 2025 , Edited by admin on Mon Mar 31 18:21:32 GMT 2025
|
||
|
WHO-VATC |
QC03BB02
Created by
admin on Mon Mar 31 18:21:32 GMT 2025 , Edited by admin on Mon Mar 31 18:21:32 GMT 2025
|
||
|
WHO-VATC |
QC03BA02
Created by
admin on Mon Mar 31 18:21:32 GMT 2025 , Edited by admin on Mon Mar 31 18:21:32 GMT 2025
|
||
|
WHO-ATC |
C03BB02
Created by
admin on Mon Mar 31 18:21:32 GMT 2025 , Edited by admin on Mon Mar 31 18:21:32 GMT 2025
|
||
|
NCI_THESAURUS |
C49185
Created by
admin on Mon Mar 31 18:21:32 GMT 2025 , Edited by admin on Mon Mar 31 18:21:32 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL1532
Created by
admin on Mon Mar 31 18:21:32 GMT 2025 , Edited by admin on Mon Mar 31 18:21:32 GMT 2025
|
PRIMARY | |||
|
DB01325
Created by
admin on Mon Mar 31 18:21:32 GMT 2025 , Edited by admin on Mon Mar 31 18:21:32 GMT 2025
|
PRIMARY | |||
|
C66501
Created by
admin on Mon Mar 31 18:21:32 GMT 2025 , Edited by admin on Mon Mar 31 18:21:32 GMT 2025
|
PRIMARY | |||
|
C050700
Created by
admin on Mon Mar 31 18:21:32 GMT 2025 , Edited by admin on Mon Mar 31 18:21:32 GMT 2025
|
PRIMARY | |||
|
3392
Created by
admin on Mon Mar 31 18:21:32 GMT 2025 , Edited by admin on Mon Mar 31 18:21:32 GMT 2025
|
PRIMARY | |||
|
8717
Created by
admin on Mon Mar 31 18:21:32 GMT 2025 , Edited by admin on Mon Mar 31 18:21:32 GMT 2025
|
PRIMARY | |||
|
7289
Created by
admin on Mon Mar 31 18:21:32 GMT 2025 , Edited by admin on Mon Mar 31 18:21:32 GMT 2025
|
PRIMARY | |||
|
998
Created by
admin on Mon Mar 31 18:21:32 GMT 2025 , Edited by admin on Mon Mar 31 18:21:32 GMT 2025
|
PRIMARY | |||
|
DTXSID9023548
Created by
admin on Mon Mar 31 18:21:32 GMT 2025 , Edited by admin on Mon Mar 31 18:21:32 GMT 2025
|
PRIMARY | |||
|
m9442
Created by
admin on Mon Mar 31 18:21:32 GMT 2025 , Edited by admin on Mon Mar 31 18:21:32 GMT 2025
|
PRIMARY | Merck Index | ||
|
73-49-4
Created by
admin on Mon Mar 31 18:21:32 GMT 2025 , Edited by admin on Mon Mar 31 18:21:32 GMT 2025
|
PRIMARY | |||
|
59743
Created by
admin on Mon Mar 31 18:21:32 GMT 2025 , Edited by admin on Mon Mar 31 18:21:32 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB10213MIG
Created by
admin on Mon Mar 31 18:21:32 GMT 2025 , Edited by admin on Mon Mar 31 18:21:32 GMT 2025
|
PRIMARY | |||
|
6307
Created by
admin on Mon Mar 31 18:21:32 GMT 2025 , Edited by admin on Mon Mar 31 18:21:32 GMT 2025
|
PRIMARY | |||
|
455E0S048W
Created by
admin on Mon Mar 31 18:21:32 GMT 2025 , Edited by admin on Mon Mar 31 18:21:32 GMT 2025
|
PRIMARY | |||
|
100000080277
Created by
admin on Mon Mar 31 18:21:32 GMT 2025 , Edited by admin on Mon Mar 31 18:21:32 GMT 2025
|
PRIMARY | |||
|
2343
Created by
admin on Mon Mar 31 18:21:32 GMT 2025 , Edited by admin on Mon Mar 31 18:21:32 GMT 2025
|
PRIMARY | |||
|
759904
Created by
admin on Mon Mar 31 18:21:32 GMT 2025 , Edited by admin on Mon Mar 31 18:21:32 GMT 2025
|
PRIMARY | |||
|
QUINETHAZONE
Created by
admin on Mon Mar 31 18:21:32 GMT 2025 , Edited by admin on Mon Mar 31 18:21:32 GMT 2025
|
PRIMARY | |||
|
200-801-7
Created by
admin on Mon Mar 31 18:21:32 GMT 2025 , Edited by admin on Mon Mar 31 18:21:32 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |